JP2022545439A5 - - Google Patents
Info
- Publication number
- JP2022545439A5 JP2022545439A5 JP2022510921A JP2022510921A JP2022545439A5 JP 2022545439 A5 JP2022545439 A5 JP 2022545439A5 JP 2022510921 A JP2022510921 A JP 2022510921A JP 2022510921 A JP2022510921 A JP 2022510921A JP 2022545439 A5 JP2022545439 A5 JP 2022545439A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- prodrug
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962889797P | 2019-08-21 | 2019-08-21 | |
| US62/889,797 | 2019-08-21 | ||
| US202063027138P | 2020-05-19 | 2020-05-19 | |
| US63/027,138 | 2020-05-19 | ||
| US202063047251P | 2020-07-01 | 2020-07-01 | |
| US63/047,251 | 2020-07-01 | ||
| US202063053663P | 2020-07-19 | 2020-07-19 | |
| US63/053,663 | 2020-07-19 | ||
| PCT/US2020/047522 WO2021035188A1 (en) | 2019-08-21 | 2020-08-21 | Novel il-21 prodrugs and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022545439A JP2022545439A (ja) | 2022-10-27 |
| JP2022545439A5 true JP2022545439A5 (cg-RX-API-DMAC7.html) | 2023-07-21 |
Family
ID=72432995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022510921A Pending JP2022545439A (ja) | 2019-08-21 | 2020-08-21 | 新規il-21プロドラッグおよびその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220289822A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4017594A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022545439A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115605504B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021035188A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| CN113286812B (zh) | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| CN114341189A (zh) | 2019-06-12 | 2022-04-12 | 奥美药业有限公司 | 全新il-15前药及其应用 |
| AU2021205981A1 (en) | 2020-01-11 | 2022-07-14 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| KR20230010251A (ko) | 2020-05-13 | 2023-01-18 | 보넘 테라퓨틱스, 인크. | 단백질 복합체의 조성물 및 그의 사용 방법 |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| KR20230157448A (ko) | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| WO2022262496A1 (en) * | 2021-06-17 | 2022-12-22 | Suzhou Fuse Biosciences Limited | Immunoconjugate molecules and related methods and compositions thereof |
| WO2023052846A2 (en) * | 2021-09-30 | 2023-04-06 | Ildong Pharmaceutical Co., Ltd. | Immunocytokine containing il-21r mutein |
| JP2025508882A (ja) * | 2022-02-28 | 2025-04-10 | エクシリオ デベロップメント, インコーポレイテッド | 標的化サイトカインおよびその使用方法 |
| WO2023230529A1 (en) * | 2022-05-26 | 2023-11-30 | Caribou Biosciences, Inc. | Cytokine-receptor fusions for immune cell stimulation |
| CN119546624A (zh) * | 2022-07-15 | 2025-02-28 | 西里欧发展公司 | 作为载体的工程化可切割Fc结构域及其使用方法 |
| CN117917438A (zh) * | 2022-10-21 | 2024-04-23 | 北京诺诚健华医药科技有限公司 | 抗体融合蛋白及其制备和应用 |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| WO2025191139A1 (en) * | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Conjugates of her2-specific antigen binding proteins and cytokines |
| WO2026003219A1 (en) * | 2024-06-26 | 2026-01-02 | Anaveon AG | Proximity activated interleukin 21 |
| EP4671273A1 (en) * | 2024-06-26 | 2025-12-31 | Anaveon AG | INTERLEUKIN 21 PROXIMITY ACTIVATED |
| CN118546233B (zh) * | 2024-07-30 | 2024-10-18 | 成都微芯新域生物技术有限公司 | 白介素-21突变体及其应用 |
| WO2026112598A1 (en) * | 2024-11-25 | 2026-05-28 | Modernatx, Inc. | Messenger rna encoding masked proteins and compositions and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| DE10045592A1 (de) * | 2000-09-15 | 2002-03-28 | Klaus Pfizenmaier | Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| EP2109620B1 (en) | 2006-12-21 | 2012-08-22 | Novo Nordisk A/S | Interleukin-21 variants with altered binding to the il-21 receptor |
| EP2190861A4 (en) * | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| US9487590B2 (en) * | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| AR099625A1 (es) | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
| AU2015244025B2 (en) | 2014-04-08 | 2019-03-21 | Boston Pharmaceuticals Inc. | Binding molecules specific for IL-21 and uses thereof |
| AU2016303497A1 (en) * | 2015-07-31 | 2018-03-01 | Tarveda Therapeutics, Inc. | Compositions and methods for immuno-oncology therapies |
| SG10201913573UA (en) * | 2015-10-01 | 2020-03-30 | Heat Biologics Inc | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
| US11617799B2 (en) * | 2016-06-27 | 2023-04-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| CN111247171A (zh) * | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| WO2020023702A1 (en) * | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
-
2020
- 2020-08-21 EP EP20768740.1A patent/EP4017594A1/en not_active Withdrawn
- 2020-08-21 US US17/635,683 patent/US20220289822A1/en not_active Abandoned
- 2020-08-21 JP JP2022510921A patent/JP2022545439A/ja active Pending
- 2020-08-21 CN CN202080077926.4A patent/CN115605504B/zh active Active
- 2020-08-21 WO PCT/US2020/047522 patent/WO2021035188A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer | |
| Ahmed et al. | Engineering anti‐GD2 monoclonal antibodies for cancer immunotherapy | |
| Forsberg et al. | Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen | |
| ES3051373T3 (en) | Site-specific glycoengineering of targeting moieties | |
| JP2021515599A5 (cg-RX-API-DMAC7.html) | ||
| ES2686692T3 (es) | Anticuerpo monoclonal anti CD146 | |
| TWI676681B (zh) | 具抗原專一性的t細胞及其用途 | |
| US20230338565A1 (en) | Antibody drug conjugate, preparation method therefor and use thereof | |
| JP2021530243A5 (cg-RX-API-DMAC7.html) | ||
| US20160208020A1 (en) | Peptide core-based multi-arm linkers | |
| TWI817190B (zh) | 抗c-Met抗體藥物偶聯物及其應用 | |
| ES3052659T3 (en) | Anti pd-1/anti-pd-l1 antibodies for enhancing the potency of superantigen mediated cancer immunotherapy | |
| CN108473588A (zh) | 新颖抗密封蛋白抗体及使用方法 | |
| JP2021520832A (ja) | キレート化された放射性核種に対する抗体 | |
| US12466869B2 (en) | Targeting of multiple antigens with multiplex CAR T cells in solid and liquid malignancies | |
| ES3054945T3 (en) | Antibodies for chelated radionuclides and clearing agents | |
| CZ330694A3 (en) | Immuno-conjugates | |
| Azadi et al. | Recent advances on immune targeted therapy of colorectal cancer using bi-specific antibodies and therapeutic vaccines | |
| Pellegrino et al. | Impact of ligand size and conjugation chemistry on the performance of universal chimeric antigen receptor T-cells for tumor killing | |
| CN106459211A (zh) | 双功能抗体及其用途 | |
| US20210228699A1 (en) | Compositions and methods for targeted immunotherapy | |
| JP2024531446A5 (cg-RX-API-DMAC7.html) | ||
| JP2023500293A (ja) | 免疫チェックポイント分子と結合可能な分子が融合したタンパク質およびその用途 | |
| Wang et al. | IgG-like bispecific antibody CD3× EpCAM generated by split intein against colorectal cancer | |
| BR112020004225A2 (pt) | conjugados de fármaco de anticorpo anti-egfr (adc) e usos dos mesmos |